Related Experiment Videos
Enalapril improved renal function and proteinuria in chronic glomerulopathies
L F Ferder1, F Inserra, H Daccordi
1Buenos Aires University School of Medicine, Argentina.
Nephron
|January 1, 1990
Summary
Enalapril therapy shows promise for patients with glomerulonephritis (GN), improving kidney function and reducing proteinuria over time. This treatment may offer a better long-term prognosis for GN patients.
Area of Science:
- Nephrology
- Pharmacology
Background:
- Glomerulopathies (GN) encompass a group of kidney diseases affecting the glomeruli.
- Patients with GN often experience reduced kidney function and significant proteinuria.
- ACE inhibitors like enalapril are used to manage hypertension and proteinuria in kidney disease.
Purpose of the Study:
- To evaluate the efficacy and safety of enalapril in patients with various forms of glomerulonephritis.
- To assess the impact of enalapril on blood pressure, renal function, and proteinuria in GN patients.
Main Methods:
- A study involving ten patients diagnosed with glomerulonephritis (membranoproliferative, membranous, focal/diffuse glomerulosclerosis, poststreptococcal).
- Patients received enalapril (10-40 mg/day), with some also receiving diuretic therapy.
- Regular monitoring of blood pressure, serum creatinine, blood urea nitrogen, creatinine clearance, and 24-hour urinary protein over a mean of 15.9 months.
Main Results:
- Blood pressure was significantly controlled in hypertensive patients.
- Serum creatinine, blood urea nitrogen, creatinine clearance, and 24-hour urinary protein showed improvement.
- No significant changes in serum potassium or adverse clinical events were observed.
Conclusions:
- Enalapril therapy may improve the long-term prognosis for patients with glomerulonephritis.
- The drug appears to maintain glomerular filtration rate and decrease proteinuria.
- Enalapril demonstrates a favorable safety profile in this patient cohort.